Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer

Cancer

Volumn 109, Issue 2, 2007, Pages 205-212

  Ramsey, Sara ^a   Lamb, Gavin W A ^a   Aitchison, Michael ^a   Graham, John ^b   McMillan, Donald C ^c  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Albumin; C reactive protein; Calcium; Cancer specific survival; Metastatic renal cancer; Performance status; Prognostic score

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CYTOKINE; FLUOROURACIL; INTERFERON;

ADULT; ADVANCED CANCER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; EVALUATION; FEMALE; GLASGOW PROGNOSTIC SCORE; HISTOPATHOLOGY; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; KIDNEY CANCER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEMORIAL SLOAN KETTERING CANCER CENTER SCORE; METASTATIC RENAL CARCINOMA COMPREHENSIVE PROGNOSTIC SYSTEM SCORE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SCORING SYSTEM;

C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INFLAMMATION; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SERUM ALBUMIN; SURVIVAL ANALYSIS;

EID: 33846248715     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22400     Document Type: Article

References (29)

1. Cancer Research UK 2002. Available at: http: //info. cancerresearchuk. org/cancerstats/types/kidney/incidence/ Accessed 2003.
2. Steineck G, Strander H, Carbin BE, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 1990;29:155-162.
3. Kriegmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology. 1995; 45:758-762.
4. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17:2859-2867.
5. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet. 1999; 353:14-17.
6. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-2524.
7. Hudes G, Carducci M, Tomczek P, et al. A Phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cancer (adv RCC). 2006 ASCO Annual Meeting proceedings, part I, vol 23. J Clin Oncol. 2006;18S. Abstract LBA4.
8. Mickisch GHJ, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966-970.
9. Ando M, Ando Y, Hasegawa Y, et al. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer. 2001;85:1634-1639.
10. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 2001;41:64-69.
11. Maltoni M, Caraceni A, Brunelli C, et al. Steering Committee of the European Association for Palliative Care. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations-a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol. 2005;23:6240-6248.
12. Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003;88:348-353.
13. Bromwich E, McMillan DC, Lamb GWA, Vasey PA, Aitchison M. The systemic inflammatory response, performance status and survival in patients undergoing alpha interferon therapy for advanced renal cancer. Br J Cancer. 2004;91: 1236-1238.
14. Casamassima A, Picciariello M, Quaranta M, et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol. 2005;173:52-55.
15. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89: 1028-1030.
16. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004;90: 1704-1706.
17. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 2006;94:227-230.
18. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006;94:637-641.
19. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology. 2006;6:450-453.
20. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
21. Sobin L, Wittekind C, eds. TNM Classification of Malignant Tumors. 5th ed. New York: John Wiley & Sons; 1977.
22. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-663.
23. Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ. 2000;320:469-472.
24. Glare P, Virik K, Jones M, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ. 2003;327:195-198.
25. McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS. Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer. 1998;31:101-105.
26. Scott HR, McMillan DC, Forrest LM, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer. 2002;87:264-267.
27. McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer. 2004;91:1993-1995.
28. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9:4653-4665.
29. Kotler DP. Cachexia. Ann Intern Med. 2000;133:622-634.